Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Improvement of glycemic control in adults with type 2 diabetes mellitus
Type 2 diabetes
impaired blood glucose control
cardiovascular disease
cardiovascular risk factors
View approved original textHide original text
This medication is an adjunctive treatment for adults with type 2 diabetes, assisting in blood glucose control by combining dapagliflozin and metformin. It is used in conjunction with diet and exercise to enhance blood glucose management and is particularly suitable for patients with type 2 diabetes whose blood glucose is not adequately controlled. Careful monitoring is required regarding the effects of dapagliflozin in patients with cardiovascular disease or risk factors. This medication is effectively used for managing type 2 diabetes.
How to take
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg.
This medicine is generally administered once daily with the evening meal.
The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg.
Patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy:
When used as initial therapy in patients who have not previously received drug treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily.
The dose should be adjusted gradually to reduce gastrointestinal adverse reactions to metformin.
In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriately titrated dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and dosage adjustments made as appropriate.
When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because any change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring.
This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet.
Renal impairment
No dosage adjustment is necessary in patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2, without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg.
Administration of this medicine is not recommended in patients with an eGFR < 45 mL/min/1.73m2.
If the estimated glomerular filtration rate (eGFR) decreases to < 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Older adults
Because metformin is excreted through the kidneys and renal function tends to decline in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
Precautions
This medication is used to help manage diabetes and control blood sugar levels. However, it should not be administered to patients with poor kidney function, severe infections, or dehydration. Caution is needed particularly in patients with moderate to severe kidney impairment, as taking this medication may pose a risk. Rarely, it can cause serious metabolic complications called lactic acidosis, which can be life-threatening; immediate medical attention should be sought if symptoms occur. Additionally, when taken with insulin or sulfonylureas, there is a risk of hypoglycemia, so blood glucose levels should be carefully monitored. During the course of treatment, urinary and genital infections may occur, so prompt treatment is necessary if infection symptoms arise. Pregnant or breastfeeding women should not take this medication and must discontinue it immediately if pregnancy is confirmed. Elderly patients or those with impaired kidney function should have their renal function regularly monitored before and during treatment, and dosage adjustment may be necessary. This medication should be temporarily discontinued before and after surgery or tests using iodinated contrast agents and restarted only after confirming normal kidney function. It may cause dehydration, hypotension, or reduced fluid volume, so special monitoring is required for elderly patients or those on diuretics. There are no specific antidotes for overdose, so appropriate treatment should be administered based on symptoms, and the metformin component can be removed via dialysis. It is advisable to avoid alcohol consumption during treatment, and regular monitoring may be necessary as vitamin B12 levels can decrease. Caution is advised as dizziness may occur when driving or operating machinery, and it should be kept out of reach of children.
Side effects
Severe lactic acidosis
severe hypoglycemia
vulvovaginitis
balanitis
genital infection
urinary tract infection
fungal infection
hypoglycemia
decreased fluid volume
thirst
Show 84 moreCollapse
diabetic ketoacidosis
dizziness
constipation
dry mouth
low back pain
dysuria
polyuria
nocturia
vulvar pruritus
genital pruritus
increased hematocrit
decreased kidney creatinine clearance
dyslipidemia
increased serum creatinine
increased blood urea
weight loss
ketoacidosis
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
rash
diarrhea
nausea
vomiting
decreased vitamin B12
Guillain-Barré syndrome
bacterial pneumonia
sialadenitis
tendinitis
chest pain
thermal burn
wrist fracture
gastrointestinal stromal tumor
malignant neoplasm of lung
uterine fibroids
atrial fibrillation
acute cholecystitis
epigastric pain
dyspepsia
abdominal discomfort
abdominal pain
gastric ulcer
irritable bowel syndrome
salivary gland mass
toothache
headache
facial paralysis
peripheral neuropathy
paresthesia
drowsiness
tremor
nasopharyngitis
pharyngitis
adenoviral conjunctivitis
herpes zoster
pneumonia
rhinitis
increased alanine aminotransferase
increased blood glucose
arthralgia
myalgia
myofascial pain syndrome
osteoarthritis
osteochondrosis
limb pain
pericapsular inflammation
tendinitis
trigger finger
weakness
fatigue
peripheral edema
edema
pain
vitamin D deficiency
hyperglycemia
urethral syndrome
cough
hyperventilation
pruritus
palpitations
insomnia
type 2a hyperlipidemia
sensorineural hearing loss
Not everyone experiences these, and they can vary from person to person.
Storage
This medication must be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the medicinal effect for a longer duration.
Appearance and packaging
Appearance
Pink or dark pink biconvex oval film-coated tablets
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.